0.7502
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Geode Capital Management LLC Acquires 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan
Xilio’s Stacey Davis recruited by Enara - The Pharma Letter
Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting - Nasdaq
Phase 2 Trial Results: Novel Tumor-Activated Therapy Shows Promise in Hard-to-Treat Colorectal Cancer - Stock Titan
50,086 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Raymond James Financial Inc. - Defense World
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World
Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World
Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World
Deals In Depth: February 2025 - insights.citeline.com
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks
Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia
Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com
Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India
Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India
Xilio Therapeutics, Inc. SEC 10-K Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView
Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq
Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat
Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn
Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP
Xilio shares soar on AbbVie collaboration deal - MSN
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE
Top Biotech Stocks To Keep An Eye On – February 12th - Defense World
AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights
자본화:
|
볼륨(24시간):